BioSpace News Archive

Concentric Analgesics, Inc. today announced the podium presentation of clinical data for vocacapsaicin, its first-in-class non-opioid lead product candidate for the management of postsurgical pain, at the 46th Annual Regional Anesthesiology and Acute Pain Medicine (ASRA) Meeting on May 13, 2021 in Orlando, Florida.

Initiative Addresses Structural and Cultural Barriers to High-quality, Culturally Competent Health Care for Black and Hispanic Women; Delivers Innovative Health Research, Education and Access Model

Seres Therapeutics to Present Key Data on Investigational Microbiome Therapeutics for Recurrent C. difficile Infection and Ulcerative Colitis at the Digestive Disease Week (DDW) Annual Meeting - Data demonstrates Seres’ leadership in microbiome sciences and therapeutics across multiple diseases -

Robust Comparative Gene Therapy Biodistribution Study Demonstrates Delivery Approach is Important Factor for Optimal CNS Targeting Results Show ICV and ICM Routes Achieve Broad and Comparable CNS Biodistribution; IT Lumbar, IV Achieve Meaningfully Lower Vector CNS Biodistribution

- Intracochlear delivery of a dual AAVAnc80 vector encoding human otoferlin results in full-length protein expression in inner hair cells of non-human primates and in durable protein expression sufficient for sustained restoration of auditory function in Otof knockout mice

Appointments of Howard Rutman, M.D., MBA, Brendan O’Leary, CFA, Kristin Murray, Steve Vicik, Ph.D., and Kristen Albright position company for success in rapid advancement of XT-150 and building a portfolio of products for chronic inflammatory conditions

AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the Company will make a virtual presentation at the Emerging Growth Conference taking place on Wednesday, May 12th, 2021.

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the appointment of Christine Coyne as Chief Commercial Officer, effective May 10, 2021

Bellerophon Therapeutics, Inc., a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, provided a clinical program update and reported financial results for the first quarter ended March 31, 2021.

Resonant Inc. (NASDAQ: RESN), a provider of radio frequency (RF) filter solutions developed on a robust intellectual property platform, designed to connect People and Things, today announced that management will present at the 16 th Annual Needham Virtual Technology & Media Conference taking place May 17-20, 2021.